From the Nasdaq MarketSite Studio, Dr. Seth Lederman, MD, Chairman and CEO of Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) (“Tonix”), talks with New to The Street’s TV Host Jane King about the Company’s successful completion of Phase 3 studies on its fibromyalgia drug. Tonix’s new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia. The drug is a non-opioid, non-addictive painkiller. Since 2009, there have been no new fibromyalgia drugs available in the marketplace. Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in the treatment success. Competitor drugs cause sleeplessness and low energy. Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish fatigue in patients. The side effects are minimal, with around 3% of patients experiencing headaches and some drowsiness. Administered as a sublingual tablet, Tonmya™ has caused tongue numbness in a very limited number of patients. Patients take the drug at bedtime, which can block brain signals that are often associated with pain, and the drug has shown improved sexual functionality. Dr. Ledermen expects the Company to submit its full report to the FDA for market approval sometime during the first half of 2024, with a full approval expectation sometime in 2025. The on-screen QR code is available during the shows; download or visit Tonix Pharmaceuticals, Inc. – https://www.tonixpharma.com/.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://www.newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list